SUMMARY Acute haemodynamic effects of single dose oral prazosin were studied in eight patients with mitral regurgitation. Heart rate, mean 
Vasodilator treatment often improves the haemodynamic state of patients with cardiomyopathy.1-5 Reduction in systemic vascular resistance results in augmented cardiac output, while a reduction in venous return effects a decline in left ventricular filling pressure. Administration of intravenous nitroprusside, an equipotent dilator of arterial resistance and venous capacitance vessels, increases forward cardiac output in patients with mitral6 or aortic regurgitation7 in association with a decrease in peripheral vascular resistance. Administration of oral hydralazine improves forward flow in mitral regurgitation and decreases the regurgitation fraction.8 Oral prazosin has been shown to exert dilatating effects on arterial and venous beds qualitatively similar to the effects of intravenous nitroprusside.9 Prazosin increases cardiac output and decreases left ventricular filling pressure in patients with heart failure.9-'1 The haemodynamic effects of oral prazosin in patients with mitral regurgitation have not been reported. (Table) . Changes in haemodynamic variables at peak effect are shown in Fig. 1 was observed (Fig. 1) . Cardiac index increased from 1-89 ±0-12 to 2-43 ±0-13 l/min per m2 (p < 0001).
Stroke volume increased from 43 ±5 to 57 ±6 ml/ beat (p < 0-001). Increases in cardiac index and stroke volume were observed in each patient (Fig. 2) . Left ventricular stroke work index also increased in each patient (mean 19.6 ±2-9 to 26.7 ±3-8 g m per m2 (p <001). A significant decline in mean pulmonary artery pressure from 45±6 to 33±4 mmHg (p <0.02) occurred. Left ventricular filling pressure decreased from 30 ±4 to 21 ±3 mmHg (p < 0-01). These changes in mean pulmonary artery and left ventricular filling pressures were noticed in each patient studied (Fig. 3) . The "v" wave in the pulmonary artery wedge pressure tracing gradually decreased in each patient from a mean of 40±6 to 20±4 mmHg (p < 0-001). The gradual decline in "v" wave after prazosin administration in a patient is shown in Fig. 4 .
Systemic and pulmonary vascular resistance decreased in each patient studied with a single dose of prazosin. At peak effect, systemic vascular resistance was reduced from 2132 ± 148 to 1491 ±94 dynes s cm-5 (p < 0-001). Similarly, pulmonary vascular resistance declined from 316 ±49 to 208 ± 43 dynes s cm-5 (p < 0 005) (Fig. 5) .
CLINICAL EVALUATION
Six of the eight patients reported noticeable improvement in symptoms of low cardiac output such as fatigue and weakness. Subjectively, dyspnoea decreased considerably in five and to a lesser degree in the remaining three patients. Examination disclosed that the extremities were warmer than in the period before prazosin. The intensity of the mitral regurgitation murmur decreased in seven patients. both systemic and pulmonary vascular beds. In each patient with mitral regurgitation, the amplitude of the regurgitant "v" wave observed in the pulmonary wedge pressure tracing declined. Since heart rate and arterial pressure fell slightly, it is unlikely that the myocardial oxygen demands increased, while the left ventricular performance improved. In this study, the haemodynamic effects of oral prazosin were first observed between 15 and 30 minutes after administration, peaked between 45 and 60 minutes, and persisted for six hours. These observations on the onset and duration of action are similar to those previously reported by us,9 20 and others. '0 11 The precise mechanism responsible for a vasodilator-associated increase in forward cardiac output in patients with valvular regurgitation lesions and heart failure is not known. It has been suggested that a decrease in systemic vascular resistance bỹ~~~~~~~~~~~~~~~~~~~~~~~~~~Ĩ~~~~~~~~~~~~~~~~~~~~~Ĩ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Ĩ~~~I vasodilators results in improved forward cardiac output and reduced regurgitation fraction.6 7 19 Studies in our laboratory have shown that in patients with heart failure, the compliance of the aorta is decreased and the vascular load much increased.2' Preliminary studies suggest that nitroprusside improves cardiac output in patients with heart failure while both peripheral resistance and characteristic aortic impedance decline. The latter finding also implies an alteration of aortic distensibility.16 The present data in a small number of subjects show that indices of cardiac performance are improved by oral prazosin in patients with severe mitral regurgitation and heart failure. Though we did not directly measure the regurgitation fraction, the increases in stroke volume and stroke work index together with the reduced pulmonary capillary "v" wave suggest enhanced forward flow in association with a decrease in vascular load in these patients. 
